Recent Advances in Optically Controlled PROTAC

Nov 28, 2023·
Muzi Ouyang (Mia)
Muzi Ouyang (Mia)
,
Ying Feng
,
Hui Chen
,
Yanping Liu
,
Chunyan Tan
,
Ying Tan
· 0 min read
DOI
Abstract
Proteolysis-targeting chimera (PROTAC) technology is a groundbreaking therapeutic approach with significant clinical potential for degrading disease-inducing proteins within targeted cells. However, challenges related to insufficient target selectivity raise concerns about PROTAC toxicity toward normal cells. To address this issue, researchers are modifying PROTACs using various approaches to enhance their target specificity. This review highlights innovative optically controlled PROTACs as anti-cancer therapies currently used in clinical practice and explores the challenges associated with their efficacy and safety. The development of optically controlled PROTACs holds the potential to significantly expand the clinical applicability of PROTAC-based technology within the realm of drug discovery.
Type
Publication
Bioengineering, 10(12), 1368
Status
Peer-reviewed Open access
publications
Muzi Ouyang (Mia)
Authors
PhD Candidate

I am Muzi Ouyang (欧阳木子) — I go by Mia. I am a PhD candidate in Chemistry at Tsinghua University, advised by Prof. Ying Tan (谭英) at the Institute of Biopharmaceutical and Health Engineering (iBHE) in Shenzhen. I work on targeted protein degradation: designing bioPROTACs that recruit E3 ligases to destroy proteins small molecules struggle to drug — and working out why that degradation sometimes fails.

My dissertation has two halves. The first is a dual-target bioPROTAC that co-degrades ERα and PI3K p85α, re-sensitizing tamoxifen-resistant breast cancer cells to endocrine therapy. The second is a KRAS-targeting degrader, where I found a resistance mutation in the hypervariable region that lets KRAS escape a multimerization-dependent platform, and used all-atom molecular dynamics to trace the conformational mechanism behind the escape.

Alongside the wet lab I work in computational protein design — Rosetta, ProteinMPNN and AlphaFold2 — including an end-to-end reproduction of the CLAIRE de novo binder-design pipeline, published openly with its debugging narrative. My training spans animal science, basic medicine and chemistry, which is why I move between wet-lab mechanism and computational design rather than choosing between them.

I expect to defend in June 2027 and am seeking postdoctoral positions starting in late 2027. If my work overlaps with your group’s, I’d be glad to hear from you — I’ll gladly send my CV. Write to me at mumumia.1009@gmail.com, or oymzmia@163.com if you are corresponding from within China.